Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, randomized, parallel, investigator- and subject-blinded, multiple-dose study assessing pharmacokinetics (PK), pharmacodynamics (PD) and safety of GB001 in healthy non-Asian (NA), non-Japanese Asian (NJA) and Japanese (JA) subjects

Next Previous
Search
Trial Profile

Phase 1, randomized, parallel, investigator- and subject-blinded, multiple-dose study assessing pharmacokinetics (PK), pharmacodynamics (PD) and safety of GB001 in healthy non-Asian (NA), non-Japanese Asian (NJA) and Japanese (JA) subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 001 (Primary)
  • Indications Allergic asthma; Asthma; Rhinosinusitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 07 Sep 2020 According to a Gossamer Bio media release, data from this trial will be presented at the Virtual European Respiratory Society International Congress 2020.
    • 05 Aug 2020 According to a Gossamer Bio media release, data from tis trial will be presented at the American Thoracic Society 2020 Virtual Conference.
    • 29 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top